Fig 1: PPM1A knockdown promoted the epithelial-mesenchymal transition by activating the TGF-β1/Smad pathway. (A and B) Type II AECs were transduced with siPPM1A. After 24 h, the mRNA (A) and protein levels (B) of PPM1A were detected with RT-qPCR and western blotting, respectively. ***P<0.001 vs. siNC. (C) Type II AECs were transduced with siPPM1A and then treated with 10 µmol/l TGF-β1/Smad inhibitor (SB431542). After 24 h, the protein levels were measured using western blotting. *P<0.05, **P<0.01, ***P<0.001. PPM1A, protein phosphatase Mg2+/Mn2+-dependent 1A; AEC, alveolar epithelial cells; si, short interfering; p-, phosphorylated; α-SMA, α-smooth muscle actin; NC, negative control.
Fig 2: PPM1A is a key target of JMSD administration for attenuating the radiation-induced EMT in primary type II AECs. PPM1A, protein phosphatase Mg2+/Mn2+-dependent 1A; JMSD, Jiawei-Maxing-Shigan decoction; EMT, epithelial-mesenchymal transition; AECs, alveolar epithelial cells; p, phosphorylation.
Fig 3: PPM1A expression level was downregulated in type II AECs following radiation treatment. Cells were treated with 8 Gy of 60Co γ-rays at a dose rate of 3.64 Gy/min at room temperature. The (A) mRNA and (B) protein levels of PPM1A were detected with reverse transcription-quantitative PCR and western blotting, respectively. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001, vs. 0 h. PPM1A, protein phosphatase Mg2+/Mn2+-dependent 1A.
Fig 4: JMSD-medicated serum attenuated the radiation-mediated inhibition of PPM1A expression in type II alveolar epithelial cells. Cells were incubated with 0, 2, 6 and 10% JSMD-medicated serum and then treated with 8 Gy of 60Co γ-rays. After 24 h, the (A) mRNA and (B) protein levels of PPM1A were detected with reverse transcription-quantitative PCR and western blotting, respectively. ***P<0.001, vs. the control; #P<0.05, ###P<0.001, vs. 8 Gy + vehicle. JMSD, Jiawei-Maxing-Shigan decoction; PPM1A, protein phosphatase Mg2+/Mn2+-dependent 1A.
Fig 5: JMSD-medicated serum attenuated radiation-induced Smad activation and epithelial-mesenchymal transition by regulating the PPM1A expression. Type II AECs, which were incubated with 6% JSMD-medicated serum, were transduced with siPPM1A (or siNC) and then treated with 8 Gy of 60Co γ-rays. After 24 h, the protein levels were measured using western blotting. *P<0.05, **P<0.01, ***P<0.001. JMSD, Jiawei-Maxing-Shigan decoction; PPM1A, protein phosphatase Mg2+/Mn2+-dependent 1A; AEC, alveolar epithelial cells; si, short interfering; NC, negative control; p-, phosphorylated; α-SMA, α-smooth muscle actin.
Supplier Page from Abcam for Anti-PPM1A antibody